I believe the Eureka Report, which recommended XTD as a buy at 29cents, has ceased coverage and hence the selling
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025